Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2021-05-09 , DOI: 10.1002/cti2.1283
Rebecca C Abbott _{1,

2} , Daniel J Verdon ₁ , Fiona M Gracey ₃ , Hannah E Hughes-Parry _{1,

2} , Melinda Iliopoulos ₁ , Katherine A Watson ₁ , Matthias Mulazzani ₁ , Kylie Luong ₁ , Colleen D'Arcy ₄ , Lucy C Sullivan ₅ , Ben R Kiefel ₃ , Ryan S Cross ₁ , Misty R Jenkins _{1,

2,

6}

Affiliation

The increasing success of Chimeric Antigen Receptor (CAR) T cell therapy in haematological malignancies is reinvigorating its application in many other cancer types and with renewed focus on its application to solid tumors. We present a novel CAR against glioblastoma, an aggressive, malignant glioma, with a dismal survival rate for which treatment options have remained unchanged for over a decade.

中文翻译：

新型高亲和力EGFRvIII特异性嵌合抗原受体T细胞有效消除人胶质母细胞瘤

嵌合抗原受体 (CAR) T 细胞疗法在血液恶性肿瘤中的日益成功正在重振其在许多其他癌症类型中的应用，并重新关注其在实体瘤中的应用。我们提出了一种针对胶质母细胞瘤的新型 CAR，这是一种侵袭性恶性胶质瘤，其治疗方案十多年来一直保持不变，存活率令人沮丧。

更新日期：2021-05-09

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文